2. Infection

Infection

Infection

Related Products

PDF 70.44 MB

Infection is a pathophysiological process that involves the invasion and colonization of a living organism (host) by disease-causing infectious agents, the reaction of host tissues to these agents and the toxins they produce, and the transmission of infectious agents to other hosts. Common infectious agents include viruses, viroids, prions, bacteria, nematodes, arthropods, and other macroparasites such as tapeworms. Hosts can fight infections using their immune system. Mammals often engage both innate and adaptive immune systems to eliminate infectious agents or inhibit their growth and transmission. When infection occurs, anti-infective drugs can suppress the infection. Several broad types of anti-infective drugs exist, depending on the type of organism targeted; they include antibacterial (antibiotic), antiviral, antifungal and antiparasitic agents.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-159955
    DC-159a 931411-93-7 98%
    DC-159a is an 8-methoxyfluoroquinolone with broad-spectrum antimicrobial activity, especially against Gram-positive pathogens. DC-159a against Peptostreptococcus, Clostridium difficile, and Bacteroides fragilis with MIC90 values of 0.5, 4, and 2 μg/mL, respectively.
    DC-159a
  • HY-159969
    MLEB-22043 98%
    MLEB-22043 is a synthetic siderophore-monobactam conjugate that is taken up into bacteria via its synthetic siderophore component by TonB-dependent transporters. Once inside the bacteria, it exerts antibacterial activity through its β-lactam component. MLEB-22043 is a broad-spectrum antibiotic with significant inhibitory activity against Klebsiella pneumoniae, Escherichia coli, Acinetobacter baumannii, and Pseudomonas aeruginosa.
    MLEB-22043
  • HY-159987
    AB-161 2848560-66-5 98%
    AB-161 is an orally active HBV RNA destabilizer and a PAPD5/7 inhibitor, with its primary action focused in the liver. AB-161 treats Hepatitis B Virus (HBV) infection by lowering the levels of Hepatitis B surface antigen (HBsAg), with an EC50 value of 2.2 nM for HBsAg. AB-161 can be used in the field of HBV infection research.
    AB-161
  • HY-160000
    Coumaperine 76733-91-0
    Coumaperine is an amide alkaloid. Coumaperine can be extracted from white piper. Coumaperine inhibits NF-κB. Coumaperine derivatives exhibit anticancer activity against non-small cell lung cancer and Hodgkin's lymphoma. Coumaperine derivatives have antibacterial activity.
    Coumaperine
  • HY-160067
    T18.3 aptamer sodium
    T18.3 aptamer sodium is an anticoagulant RNA aptamer targeting FV/Va and eliminates the interaction of FV/FVa with phospholipid membranes. T18.3 aptamer sodium exhibits clinically relevant anticoagulant activity in plasma and whole blood and acts synergistically with low molecular weight heparin. The anticoagulant activity of T18.3 aptamer sodium is effectively and rapidly reversed by protamine sulfate.
    T18.3 aptamer sodium
  • HY-160168
    BTK-IN-31 98%
    BTK-IN-31 (Compound 2) is a selective, non-covalently reversible, and blood-brain barrier (BBB) permeable Btk inhibitor. BTK-IN-31 has research potential in immune disorders, cancer, cardiovascular disease, viral infections, inflammation, metabolic/endocrine dysfunction, and neurological disorders.
    BTK-IN-31
  • HY-160198
    Vaccine adjuvant-1 98%
    Vaccine adjuvant-1 is an vaccine adjuvant is a vaccine adjuvant containing an oil phase, emulsifying agent and water.
    Vaccine adjuvant-1
  • HY-160223
    ssVACV-70mer sodium
    ssVACV-70mer sodium is a 70 bp single-stranded oligonucleotide containing viral DNA motifs that derive from the vaccinia virus DNA. Unlike its double-stranded counterpart dsVACV 70mer, ssVACV 70mer is not IFN-inducer.
    ssVACV-70mer sodium
  • HY-160255
    N-Cbz-L-Cysteine 53907-29-2 98%
    N-Cbz-L-Cysteine (Cbz-cysteine) (compound 5) is a potent β-lactamase II inhibitor with a Ki value of 97 µM.
    N-Cbz-L-Cysteine
  • HY-16035A
    Alatrofloxacin mesylate 146961-77-5 98%
    Alatrofloxacin mesylate is an antibiotic with antibacterial activity. Alatrofloxacin mesylate exhibits significant hydrophilicity in the aqueous phase, forming a very stable suspension. The degradation products of Alatrofloxacin mesylate become hydrophobic upon exposure, causing aggregation of its particles. The long-term stability of Alatrofloxacin mesylate is closely related to its polar interaction. The changes in surface tension characteristics of Alatrofloxacin mesylate particles under different lighting conditions affect their physical and chemical properties.
    Alatrofloxacin mesylate
  • HY-160548
    mTOR inhibitor-18 2170358-67-3 98%
    mTOR inhibitor-18 (Example 106) is a mTOR inhibitor. mTOR inhibitor-18 can be used for mTOR related research, such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine function disorders and neurological disorders.
    mTOR inhibitor-18
  • HY-160611
    TgENR-IN-1 1428626-91-8 98%
    TgENR-IN-1 (Compound 5a) is an inhibitor for Toxoplasma gondii enoyl reductase (TgENR), which inhibits 25% TgENR at 1 μM. TgENR-IN-1 exhibits toxicity with an IC50 of >10 μM in parasite tissue.
    TgENR-IN-1
  • HY-160633
    PfFAS-II inhibitor 1 1459704-68-7 98%
    PfFAS-II inhibitor 1 (Compound 3) is a Plasmodium falciparum type II fatty acid biosynthesis pathway (PfFAS-II) inhibitor, with an IC50 of 0.63 μM for PfFabI enzyme. PfFAS-II inhibitor 1 has antimalarial activity.
    PfFAS-II inhibitor 1
  • HY-160634
    BRD4 Inhibitor-31 1446233-35-7 98%
    BRD4 Inhibitor-31 (Example 136) is a BRD4 inhibitor (Kis: 0.234 μM and 0.295 μM for BRD4 BD1 and BRD4 BD2 respectively). BRD4 Inhibitor-31 can be used for research of inflammatory diseases, cancer, and AIDS.
    BRD4 Inhibitor-31
  • HY-160644
    8PC 952588-30-6 98%
    8PC is a the ligand of InhA-NADH-JPM, and can be used for study of tuberculosis.
    8PC
  • HY-160648
    InhA-IN-6 1040406-33-4 98%
    InhA-IN-6 (compound 8) is InhA inhibitor with the IC50 of 90 nM.
    InhA-IN-6
  • HY-160653
    JPL 952588-18-0 98%
    JPL is a InhA-cofactor-ligand 3FNG inhibitor, and can be used for study of tuberculosis.
    JPL
  • HY-160669
    Antibacterial agent 198 1649473-36-8 98%
    Antibacterial agent 198 (Compound 16) is an antibacterial agent against gram positive Staphylococcus aureus and strains of Entercoccus.
    Antibacterial agent 198
  • HY-160678
    InhA-IN-7 952588-17-9 98%
    InhA-IN-7 (Compound 11) is a Triclocan (HY-B1119) derivative with inhibitory activity towards enoyl-acyl carrier protein reductase (InhA) with an IC50 of 96 nM. InhA-IN-7 inhibits proliferations of Mycobacterium tuberculosis wildtype and mutant strains with MICs ranging from 19 to 75 μM.
    InhA-IN-7
  • HY-160679
    BaENR-IN-1 1071966-17-0 98%
    BaENR-IN-1 (Compound 5) is an inhibitor of Enoyl-Acyl Carrier Protein Reductase (ENR) (IC50= 7.7 μM). BaENR-IN-1 blocks the synthesis of fatty acids essential for bacterial growth by inhibiting the bacterial enzyme ENR. BaENR-IN-1 shows activity against bacteria.
    BaENR-IN-1
Cat. No. Product Name / Synonyms Application Reactivity